Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Processa Pharmaceuticals, Inc. Director's Dealing 2025

Jul 28, 2025

35172_dirs_2025-07-28_2383c80d-d12c-46b3-92b9-b0998cc5d9db.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2025-07-28

Reporting Person: Guy Wendy (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-07-24 Restricted Stock Units $0 A 1366046 Acquired Common Stock (1366046) Direct

Footnotes

F1: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,349,245 shares are subject to stockholder approval of the revised Omnibus Plan.

F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.